ENDRA Life Sciences Inc. is a medical technology company focused on developing advanced ultrasound technologies for clinical use. Its main product, the Thermo-Acoustic Enhanced Ultrasound (TAEUS) platform, is designed to provide imaging capabilities similar to MRI, but at a fraction of the cost and at the point of care. ENDRA’s technology is primarily aimed at improving the diagnosis and monitoring of liver disease, particularly non-alcoholic fatty liver disease (NAFLD), with potential applications in other conditions. The company is headquartered in Ann Arbor, Michigan, USA, and its shares are listed on the NASDAQ.

ENDRA Life Sciences

ENDRA Life Sciences (NDRA) Q4 2025 Summary | Quartr

Google Play

App Store

App links

Article Categories

Prefooter USP - CTA App

Dig deeper into the Visa Inc fundamentals on Quartr.

Features CTA

Product

Use cases

Discover

Resources

Company

email

Features

Platforms

Featured article

Pricing

Contact sales

Simple CTA

events-root

ENDRA Life Sciences Inc

Q2 saw a $7.3M raise, 26% expense cut, narrowed loss, and leadership changes amid ongoing risks.

Q2 2024

Pursuing a dual strategy of medical imaging innovation and major cryptocurrency investment.

Registration Filing

Key votes include director elections, share authorization, reverse split, and auditor ratification.

Proxy Filing

Shareholders will vote on director elections, share increases, a reverse split, and warrant issuances.

Shareholders will vote on director elections, compensation, auditor, share increase, and governance changes.

Facing Nasdaq delisting, a reverse stock split will be proposed to regain compliance.

Shareholders to vote on a reverse stock split to help maintain Nasdaq listing and increase share price.

Vote sought on a reverse stock split to maintain Nasdaq listing and avoid delisting risk.

Six key proposals—including a 50-fold share authorization increase—are up for shareholder vote.

### Executive summary
- Initiated a strategic alternatives review to maximize shareholder value, with no set timetable for completion.
- Achieved significant clinical milestones for TAEUS Liver, demonstrating strong correlation with MRI-PDFF and robust repeatability, supporting its use in clinical practice and pharmaceutical trials.

### Financial highlights
- Operating expenses for Q4 2025 decreased to $1.6M from $4.3M in Q4 2024; full-year 2025 operating expenses fell to $5.8M from $10.8M in 2024.
- Net loss for Q4 2025 was $3.2M, improved from $4.2M in Q4 2024; full-year net loss was $7.0M, down from $11.5M in 2024.
- Cash used in operations in Q4 2025 increased to $1.6M from $1.5M in Q4 2024.
- As of December 31, 2025, cash and cash equivalents were $762K, with an additional $2.0M in digital assets.

### Outlook and guidance
- Continued execution of strategic and operating initiatives during the strategic review process.
- Management remains confident in the long-term potential of TAEUS Liver and its value proposition for patients, clinicians, and shareholders.

ENDRA Life Sciences (NDRA) Q4 2025 earnings summary

Q4 2025 earnings summary

Executive summary

Financial highlights

Outlook and guidance

Latest events from ENDRA Life Sciences